¤E¤Q¤»¦~«×¤º¬ì±M¬ìÂå®v¦Ò¸Õµ§¸ÕÃD -- ¤ßŦ¬ì

(C) 1.¥H¤U±Ô­z¦óªÌ¤£¥¿½T?
A.¤ß¿é¥X¶q (cardiac output) ¨ú¨M©ó¤ß³t²v (heart rate)¡B«e­t²ü (preload)¡B«á­t²ü (afterload) ¤Î¤ß¦Ù¦¬ÁY¤O (contractility)
B.¥D°Ê¯ßÀ£ (¦åÀ£) = ¤ß¿é¥X¶q (cardiac output) x ¨t²Î¦åºÞªý¤O (systemic vascular resistance) + ¥k¤ß©ÐÀ£¡C³q±`¦]¥D°Ê¯ßÀ£ >>¥k¤ß©ÐÀ£¡A¦]¦¹¥k¤ß©ÐÀ£¥i¬Ù²¤¡A ¦Ó¥D°Ê¯ßÀ£ (¦åÀ£) = ¤ß¿é¥X¶qx¨t²Î¦åºÞªý¤O
C.¯ßÀ£ (pulse pressure) ¦bµL°Ê¯ßªý¶ë®É¤Ï¬M¯ß·i±j®z¡C¯ßÀ£¨ú¨M©ó¤ß°Ê®e¿n (stroke volume) »P°Ê¯ß¶¶À³©Ê (arterial compliance)¡C¯ßÀ£»P¤ß°Ê®e¿n§e¥¿¬ÛÃö¡A»P°Ê¯ß¶¶À³©Ê¥ç§e¥¿¬ÛÃö
D.ªÍ°Ê¯ßÀ£ = ªÍ¦å¬y¶q* x ªÍ¦åºÞªý¤O + ªÍÀR¯ßÀ£¡C*¦pµL¤ßŦ¥ª¥k¤À¬y (left-to- right or right to-left shunt) ®É¡AªÍ¦å¬y¶q = ¤ß¿é¥X¶q
E.¥H¤W¬Ò¥¿½T
 
(B) 2.¦b¤U¦CÀVÀR¯ßÀ£¤Wª@±¡ªp¡A¦b¦ó¶µ©|¥i¤p¤ß¨Ï¥Î§Q§¿¾¯¡H
A.¤ß¥]Ån¶ñ¶ë¡]cardiac tamponade¡^¡C
B.ºC©Ê³¬Âê©Ê¤ß¥]Ånª¢¡]chronic constrictive pericarditis¡^¡C
C.¤U¾À¤ß¦Ù±ð¶ë¦X¨Ö¥k¤ß«Ç±ð¶ë¡C
D.¤ß°IºÜ¯f¤H¸g¨Ï¥Î§Q§¿¾¯«á©|¦³¸}¸~¡A¦ý¦³°_§¤©ÊÀY·w¤Î§C¦åÀ£¡C
E.¥H¤W¬Ò¾A¦X¨Ï¥Î§Q§¿¾¯
 
(C) 3.¤U¦C²Ó­M¦óªÌ»P°Ê¯ßµ°ª¬µw¤Æµo¥Í¤Î¶i®i¤§¯f²z¾÷ÂàµLÃö¡H
A.¦åºÞ¤º¥Ö²Ó­M (endothelial cell)
B.¥­·Æ¦Ù²Ó­M (smooth muscle cell)
C.B«¬²O¤Ú²y (B lymphocyte)
D.¢â«¬²O¤Ú²y (T lymphocyte)
E.¤j§]¾½²Ó­M (macrophage)
 
(C) 4.48·³¤k©Ê¥D¶D´e¯Ý¡A°¸¦³¯t·w¨Ã¦³¹B°Ê©Ê©I§l§xÃø¡C²z¾ÇÀˬd¯ß¸õ64/min¡A¤ßŦ¤j¤p¥¿±`¡A¦³S4¡A¦b¯Ý°©¥ª½t²Ä¥|¦Ø¶¡¦³Gr IV/VI®g¥X«¬¤ßÁY´ÁÂø­µ¡A¦V¤ß¦y¤ÎÀV³¡©ñ´²¡C¦å¦æ¤O¾ÇÀ£¤O¡]mmHg¡^¦p¤U¡G¥k¤ß©Ð¥­§¡À£¡G6¡F¥k¤ß«Ç43/8¡FªÍ°Ê¯ß¡G43/16¡]¥­§¡À£28¡^¡FªÍ°Ê¯ß·¤À£¡G¥­§¡À£22¡F¥ª¤ß«Ç¡G227/33¡F¥D°Ê¯ß139/72¡]¥­§¡À£98¡^¡A¯f¤H¤§¤ßŦ¯f¶EÂ_¬°¡G
A.¹¬´Uä¯U¯¶¡C
B.¹¬´U䳬Âꤣ¥þ¡C
C.¥D°Ê¯ßä¯U¯¶¡C
D.¥D°Ê䳬Âꤣ¥þ¡C
E.¤T¦y䳬Âꤣ¥þ¡C
 
(E) 5.¤U¦C A-D·f°t±Ô­z¦óªÌ¤£¥¿½T?
A.¸¡/­Iµh, Grey Turner sign - ¸¡°Ê¯ß½F¯}µõ (rupture of abdominal aorta)
B.«æ©Ê¯Ýµh, ¥Ö¤U®ð¸~ - ­¹¹D¯}µõ (esophageal rupture)
C.«æ©Ê¯Ýµh, ©I§l§xÃø, ®ðºÞ°¾¦V (deviation) - ±i¤O©Ê®ð¯Ý (tension pneumothorax)
D.«æ©Ê¯Ýµh, ¥ª¤WªÏ¯ß·i®ø¥¢ - °Ê¯ß­éÂ÷ (aortic dissection)
E.¥H¤W¬Ò¥¿½T
 
(D) 6.¤U¦C§Ü¦å¤pªO¾¯¤Î§Ü¾®¦å¾¯¤§§@¥Î¾÷Âà¡A¦óªÌ¬°«D?
A. Aspirin-§í¨î cyclooxygenase¡A¦ÓªýÂ_thromboxane¤§²£¥Í
B.Ticlopidine¡Bclopidogrel - ADP¨ü®e¾¹ (receptor) ªýÂ_¾¯
C.Abciximab¡Btirofiban - glycoprotein IIb/IIIa¨ü®e¾¹¤§ªýÂ_¾¯¡AªýÂ_¦å¤pªO»Pfibrinogen¤§µ²¦X
D.Heparin-ª½±µ¤§§Üthrombin¾¯ (direct anti-thrombin)
E.Coumadin (warfarin) - §í¨îºû¥L©RKÄÝ©Ê (Vit. K dependent) ¾®¦å¦]¤lII, VII, IX¤ÎX
 
(B) 7.¤U¦CÄòµo©Ê°ª¦åÀ£¡A¦óºØ³Ì®e©ö¶EÂ_?
A.Renovascular hypertension
B.Coarctation of aorta
C.Primary aldosteronism
D.Cushing syndrome
E.Pheochromocytoma
 
(B) 8.¦³Ãö©ó«æ©Ê¤ß¦Ù±ð¶ëµo¥Í¤ß«ÇÅÖºûŸ°Ê (Vf, ventricular fibrillation) ªº¤U¦C±Ô­z¡A¦óªÌ¬°«D?
A.Primary Vf¤j³¡¥÷¦bAMIµo¥Í¤§ÀY12¤p®É
B.µ¹¤©lidocaine¹w¨¾Vf¡A¦³§U©ó´î¤ÖAMI¤§¦º¤`²v
C.µ¹¤©¹w¨¾©Êlidocaine¡A¦³§U©ó´î¤Öprimary Vf ªºµo¥Í
D.Primary Vf ¤£­P¼vÅT¤ß¦Ù±ð¶ëªø´Á¦s¬¡²v
E.¦b«æ©Ê¤ß¦Ù±ð¶ë«á´Á¦]pump failure ²£¥Íªº secondary Vf¡A¨ä¹w«á¸û®t
 
(B) 9.Ãö©ó«æ©Ê¤ß¥]Ånª¢ (acute pericarditis) ¤§±Ô­z¡A¦óªÌ¬°«D¡H
A.¨å«¬¯Ýµh¡A¦b§l®ð¤Î¥­½ö®É¥[¼@
B.12¾Éµ{¤ß¹q¹Ï§e²{§½³¡©Ê¾Éµ{ST¬q¤Wª@¡]¦p¦bin II, III¤ÎaVf¡^¥B¦³¬ÛÀ³©ÊST¬q¤U­° (reciprocal ST depression)
C.¦bÄu©Ê¸`«ß (sinus rhythm) ®É¡A¨å«¬¤§¤ß¥]Ån¼¯À¿­µ (friction rub¡^¥Ñ3­Ó®É¬Û²Õ¦¨ (triple phase)- §Y¦b¤ß«Ç¦¬ÁY¡A¤ß«ÇµÎ±i»P¤ß©Ð¦¬ÁY®É
D.¯f±¡°lÂÜ®ÉÀ³ª`·NÀVÀR¯ßª¬ºA¡A¦pÀR¯ßÀ£¶}©l¤Wª@¡A«hÀ³¦Ò¼{µo¥Í effusive - constrictive pericarditis ©Î¤ß¥]¶ñ¶ë (cardiac tamponade)
E.¥H¤W¬Ò¥¿½T
 
(E) 10.¦b¤U¦C¦óºØ±¡ªp¤£©y¨Ï¥ÎÂà¤ÆúC§í¨î¾¯ (angiotensin converting enzyme inhibitor) ©Î angiotensin receptor blocker (ARB) ?
A.¨â°¼µÇ°Ê¯ß¯U¯¶
B. ¦³¹ï¦å¬y¦³ÄY­«functional or organicªý¤OªÌ (¦pÄY­«¤§¥D°Ê¯ßä¡B¤G¦yä¯U¯¶©ÎªÍ°Ê¯ß°ªÀ£µ¥)
C.¤w¦³©ÎÃhºÃ¦³«e­t²ü (preload) ¥i¯à¤£¨¬±¡ªpªÌ (¦p¾É¦]©ó¹Ã¦R¡B¸¡Âm¡B¥X¦å¤Î¹L·í¨Ï¥ÎÀR¯ßÂX±i¾¯©Î/¤Î§Q§¿¾¯µ¥)
D.¦³°_§¤©Ê§C¦åÀ£ªÌ
E.¥H¤W±¡ªp¬Ò¤£©y¨Ï¥Î¦¹ÃþÃĪ«
 
(E) 11.¦³Ãö¤ßŦÂH²G½F (myxoma) (1) -(5) ±Ô­z¤§²Õ¦X¡A¦óªÌ¬°¥¿½T ?1. ÂH²G½F¬°³Ì±`¨£¤§­ìµo©Ê¤ßŦ´c©Ê¸~½F2. ¥i¯à¥HªÍÆ{¦å¡B°Ê¯ß®ê¶ë¡Bµo¿N¡B©ü³Ö¡BÖ`¦ºµ¥ªí²{3. ¤ßŦť¶E¡AÂø­µ¥i¯à¦]Åé¦ì§ïÅܦӦ³©ÒÅܤÆ4. ¤ßŦ¶W­µªi¬°³Ì¦nªº¶EÂ_¤u¨ã5. ¶EÂ_«á¤@¯ë¤£§@¤ß¾ÉºÞÀˬd¡AÀ³§Y®É¶}¤M
A.1 + 3 + 4
B.1 + 2 + 4 + 5
C.3 + 4 + 5
D.1 + 2 + 3 + 4
E.2 + 3 + 4 + 5
 
(D) 12.¦³Ãö1 - 5 ±Ô­z¤§²Õ¦X¡A¦óªÌ¬°¥¿½T? 1. ¤ò¦a¶Àdigoxin¡A¤A«¬¥æ·P¯«¸gªýÂ_¾¯¡A¶tÂ÷¤lªýÂ_¾¯¤§verapamil©Îdiltiazem¹ï¤ß©ÐŸ°Ê¦³±±³t§@¥Î (rate control)¡A¥i¦³®Ä±±¨î§Ö³t¤§¤ß«Ç³t²v 2. ¦b¥Òª¬¸¢¥\¯à¤®¶i¯f¤H±±¨î¤ß«Ç³t²v¤§­º¿ïÃĪ«¬°¤A«¬¥æ·P¯«¸gªýÂ_¾¯propranolol 3. Amiodarone¥Î©óªvÀø¤ß©ÐŸ°Ê¥D­n¬°±±«ß§@¥Î (rhythm control) -- ±N¤ß©ÐŸ°ÊÁB¥¿¬°Äu©Ð²v (sinus rhythm) ©Î¹w¨¾¤ß©ÐŸ°Ê¦Aµo¥Í¡C¨Ï¥Îamiodarone¦³¥i¯à¤zÂZ¥Òª¬¸¢¥\¯àÀˬd 4. ¨Ï¥Îdigoxin±±¨î¤ß«Ç³t²v¡A¤£¥²ºÊ±±¦å¤¤¿@«× 5. Digoxin¦X¥Îamiodarone¡Bverapamil©Îaldactone¦³¥i¯àµo¥ÍÃĪ«¥æ¤¬§@¥Î (drug interaction)¡A¾É­Pdigoxin¦å¤¤¿@«×¼W¥[
A.1 + 3 + 4
B. 1 + 2 + 5
C.3 + 4 + 5
D.1 + 2 + 3 + 5
E. 1 - 5 ¬Ò¥¿½T
 
(A) 13.¹ïÄY­«¥D°Ê¯ßä¯U¯¶»Pªý¶ë©ÊªÎ«p©Ê¤ß¦Ù¯f¨âªÌ1 - 5 ±Ô­z¤§²Õ¦X¡A¦óªÌ¬°¥¿½T?1. ¨âªÌ¦³¬Û¦ü¤§Á{§Éªí²{¥]¬A©I§l§xÃø¡B¯U¤ß¯g¡B©ü³Ö¤ÎÖ`¦º2. ¨âªÌÀV°Ê¯ß·i°ÊÅã¥Ü©µ¿ð¤W³» (slow upstroke)3. ¨âªÌ¤ß¹q¹ÏÅã¥Ü¥ª¤ß«ÇªÎ¤j4. ¦b«áªÌ¦¬ÁY´ÁÂø­µ¦b§@Valsalva°Ê§@®É¤Î¯¸¥ß®ÉÅܤj¡AÃÛ¤U®ÉÅܤp5. ¤ß°IºÜ®É¨âªÌ¬Ò¥i¨Ï¥ÎdigoxinªvÀø
A.1 + 3 + 4
B. 1 + 2 + 5
C. 3 + 4 + 5
D.1 + 2 + 3
E.1 - 5 ¬Ò¥¿½T
 
(A) 14.´NÀI¦V¦]¯À(Risk factor)¤§­P¯f±j«×¦Ó¨¥,¤U¦C¦ó²Õ¸sªº°O­z¬O¥¿½Tªº ;1.©â·Ï¹ï«a¤ß¯f(coronary heart disease) ¤Î¥½±é¦åºÞ¯f(Peripheral artery disease)¤§­P¯f±j«×»·¤ñ¸£¤¤­·¬°­«2.°ª¦åÀ£·|­««×¼vÂQ¸£¤¤­·¤§µo§@3.¦å²M¤¤°ªLDL-C¤Î/©Î§CHDL-C¦h¨£©ó«a¤ß¯f4.¿}§¿¯f¹ï¤¤­·ªº¦MÀI©Ê»·¤j©ó«a¤ß¯f5.¦å²MC-reactive protein¤§¤Wª@¹ï¤¤­·ªº¦MÀI©Ê»·¤j©ó«a¤ß¯f
A.1+2+3
B.4+5
C.1+3+5
D.2+4
E.1+4+5
 
(C) 15.¯f¤H¬O43·³¥Í·N¤H,¸g±`¥X°ê¸g°Ó,©ó¤­¤ë¤Q¤»¤é¦]¦³¶i®i©Ê©I§l§xÃø¤D¦Ü«æ¶E¨DÂå,¯f¤H©ó¤­¤ë¤T¤é®È¦æ¤é¥»®É¬ð¦³©¿§N©¿¼ö,¦ñ¦³°®«y©I§l§xÃø¤Î¯Ý´e,¥B·í®É¦Û¶q¦åÀ£¥u¦³90/60 mmHg,¨ä«á¯gª¬µy¸Ñ,¤D¦^°ê¥ð¾i,¦ý¦b¤­¤ë¤Q¥|¤é¹B¾±©Ê©I§l§xÃø³vº¥Âà¼@.²z¾Ç:¦åÀ£95/75 mmHg;¤ß¸õ78/¤À¡A³W«h«ß¸õ;ÀVÀR¯ß¥¿±`,¦ý¤ßŦÅãµÛÂX¤j,S1¤ÎS2³£Âà®z;³£µL¤ßÂø­µ,¨ä¥L²z¾Ç©Ò¨£©|ºÙ¥¿±`.¯f¤H¦³°ª¦åÀ£¤Î°ª¯×¦å¤Î¨C¤Ñ©â·Ï1.5¥]¦³¤T¤Q¦~¤§¤[,¥B¦b1.5¦~«e´¿¦³µu°}©Ê¸£¯Ê¦åµo§@.,¥Í¤ÆÀˬd:¥u¦³GOT 50u/L;GPT 25u/L;Troponin I(ng/ml), CK,(U/L)CK-MB(U/L):¤­¤ë¤Q¤»¤é - 5.65,246,17.1;¤­¤ë¤Q¤C¤é- 3.74,190,10.1;¯Ý³¡X¥ú¤Î¤ß¹q¹Ï ¦p¥Ü,½Ð°Ý¤U¦C¦óªÌ¬O³Ì¦³¥i¯àªº¶EÂ_?
A.«DST¤Wª@«æ©Ê¤ß¦Ù±ð¶ë¯g
B.¤ßµ±µh
C.¤ß¦Ùª¢¦X¨Ö¤ß¦Ù¯fÅÜ
D.°ª¦åÀ£©Ê¤ßŦ¯f
E.ªÍ°Ê¯ß¦å®ê¯g
 
(D) 16.¯f¤H¬O¦ì31·³·~°È±À¾P­û¡A´¿¬OÄx²y°ê¤â¡A³Ìªñ¤@©P®É¦³¹B°Ê©Ê©I§l§xÃø¡A¦P®É¦ñ¦³Âù¸}¤ô¸~¡A¦]¦Ó¦í°|¶EÀø¡C¯f¤H¥|¦~«e´N´¿¦³´X¦¸ª±²y«á¦³«y¦å·ð¤Î³vº¥¹B°Ê­@¨ü¤£¨¬¡A±q¦¹°±¤î³o­Ó¹B°Ê¶Ý¦n¡C¯f¤H´¿¦³¨DÂåªvÀø¡A¨Ï¥ÎCordarone, Furosemide ¤ÎSpirolactone¤§°O¿ý¡C²z¾ÇÀˬd¡G¦åÀ£98/64 mmHg¡F¤ß¸õ,60/min¡A³W«h«ß¸õ¡AÀVÀR¯ß«ã±i¡A¦³©úÅãvªi¡A¯Ý³¡¦³¿B­µ¡A¥ª¥k¤ß«ÇÅãµMÂX¤j¡A¦b¤ß¦y¦³Gr III/VI Pansystolic blowing murmurª½¶Ç¥ªµÅºÛ¡A¦P®É¦³S3¥i»D¡AP2¤]µy¥[±j,¨ÃµL¨xµÊ¸~¤j¤Î¸¡¤ô¤§¥X²{,°ßÂù¸}¤ô¸~¡C¤ß¹q¹Ï¡B¯Ý³¡X¥ú¡B¶W­µªi¤ß¹Ï¤Î¦å¦æ¤O¾ÇÀˬd¡A¦p¹Ï©Ò¥Ü¡G¥»¯f¤H³Ì¥i¯àªºÁ{§É¶EÂ_¬O
A.°ª¦åÀ£©Ê¤ßŦ¯f
B.¯Ê¦å©Ê¤ßŦ¯f
C.ªÍ©Ê¤ß
D.ÂX±i©Ê¤ß¦Ù¯f
E.ªÎ«p©Ê¤ß¦Ù¯f
 
(B) 17.75·³¤k©Ê¥D¶D³Ìªñ¥b¦~³vº¥¥[­«ªº¹B°Ê©Ê©I§l§xÃø¤Î´¿¦³¼Æ¦¸©ü³Ö,¯f¤H¤_10¦~«e¦]¹¬´Uä¯U¯¶±µ¨ü¾÷±ñ©Ê佤¸m´«³N,¨ä«á¯f±¡¥­¶¶,¤£·Nªñ¥b¦~¶}©l¹B°Ê­@¨ü¤£¨¬,®É±`«_¦½¶¡¦³µu°}©ü³Ö,²z¾ÇÀˬd:¦åÀ£,103/60 mmHg;¤ß¸õ,80/min ³W«ß,ÀVÀR¯ß¯B±i,¦³Vªi,¤ßŦÂù°¼ÂX¤j,¥iºN¨ì¥ª¥k¤ß«Ç¬ð¸õ(Heave),¦b¥D°Ê¯ß°Ï¦³GrIII-IV/VI Systolic ejection murmur¦P®É¶ÇÁn¦ÜÀV°Ê¯ß,A2´îÁn,¦b¤ß¦y°Ï¥iÅ¥¨ì¹¬´Uä¶}¦XºVÀ»Án(Opening & closing click),¦b¥k°¼¯Ý°©¤U½t³B¦³§l®ð¥[±jªºGr II/IV Systolic blowingmurmur,¦³»´«×¸¡¤ô¤ÎÂù¸}¯B¸~.¸g¶W­µªi¤ß¹Ï½T©w¥D°Ê¯ßä¯U¯¶,¬ï¶V佤À£¤O®t¦³69 mmHg,¥D°Ê¯ßä¶}¤f­±¿n0.9 cm2,¤H¤u¹¬´Uä¥\¯à¥¿±`.¥ª¤ß«ÇµÎ±i/¦¬ÁYª½®|50/33;¥ª¤ß©Ð,43 mm;¥ª¤ß«Ç¾À,9 mm¡C¾ÉºÞÀˬdµý¹ê AS + AR + TR¤Î¥¿±`¤H¤u¹¬´Uä.¥»¯f¤H¨ÌÕu²{¦æAHA/ACCªvÀø«ü¤ÞÀ³¦æªº³B¸m,¤U¦C¦óªÌ¬O¥¿½Tªº?
A.¦Ñ¦~°ªÄÖ,¤£¾A¥~¬ì¤â³N
B.¦³¯gª¬ªº¥D°Ê¯ßä¯U¯¶À³³w¦æ¥~¬ìä¯ß¸m´«¤â³N
C.¥»¯f¨Ò±o¥H¾ÉºÞ®ð²yÂX±i³N§@¥D°Ê¯ßä¾ã§Î¤â³N
D.¥»¯f¨Ò¥Hdigoxin ¤Î§Q§¿¾¯ªvÀø§Y¥i
E.«O¦uªº´_°·ªvÀø³Ì¦w¥þ
 
(E) 18.¦b¹êµýÂå¾Ç±j«×Class 1¤ÎLevel A ªº½×ÂI,¹ï«DSTªi¬q¤Wª@¤ß¦Ù±ð¶ë(Non ST elevation myocardial infarction,NSTEMI) ¯f¤H¤§¤U¦C¦óºØª¬ªp,¥i¤£¥²³w¦æ¦­´Á¿n·¥³B¸m(Early invasive management).
A.¦b¦í°|ªvÀø¤¤¤´¦³«ùÄò©Ê¤ßµ±¯k
B.¦åÀ£ 88/76 mmHg
C.«ùÄò©Ê¤ß«Ç©Ê§Ö¸õ(Sustain ventricular tachycardia)
D.·s²{STªi¬q¤U¨H(ST depression)
E.¦å²MTroponin I, 0.5 ng/ml
 
(A) 19.¤U¦C¦³Ãö«DST¤Wª@«æ©Ê«a¤ß¯g­Ô¸s(Non ST elevation ACS)ªºÁ{§É°O­z,¦óªÌ¬O¤£¥¿½Tªº
A.¦­´Á³qºZ¦åºÞ(Early revascularization)¥i§ïµ½«DST¤Wª@«æ©Ê¤ß¦Ù±ð¶ë(NSTEMI)
B.¥»¯g­Ô¸s¦h¨£©ó¦Ñ¤H,¦³¤ß¦Ù±ð¶ë¯f¥vªÌ,¦³¦hºØ¤ß¦åºÞ¯f¦MÀI¦]¯ÀªÌ
C.¤T¤À¤§¤G¦¹Ãþ¯f¤Hªº«aª¬°Ê¯ß¯U¯¶¤Ö©ó50%,¨ä¦åºÞ³y¼v¦h§e¨£«D¹ïºÙ©Ê,ªøªu©Ê¤Î°~®kÅs¦±¯U¯¶
D.Enoxaparin¤ñ¶Ç²ÎªºHeparin¹ï¥»¯g³Ì¨ãÀø®Ä
E.«DST¤Wª@«æ©Ê¤ß¦Ù±ð¶ë¯g¯f¤H¤§¦í°|¦º¤`²v¤ñST¤Wª@«æ©Ê¤ß¦Ù±ð¶ë¯g¯f¤H¬°§C,¦ý´Nªø´Áªº¦º¤`²v¦Ó¨¥,¨âªÌ¬O¤£¤À°a¸þªº
 
(C) 20.¦³Ãö¤ßŦ°IºÜªvÀøªº¹êµýÂå¾Ç¥]¬A¤U¦C¦U¶µ:1.ACE inhibitors¹ïµL¯gª¬©Î­««×¯gª¬ªº¯f¤H³£À³¸Ó¨Ï¥Î¡B°£«D¦³Ãø§Ô«y¹Â¡BµÇ¥\¯à°h®i©Î§C¦åÀ£¤§µo¥Í2.Beta-blockers¤£À³¦b¤£Ã­©w«¬ªº¤ß°IºÜ¡B§C¦åÀ£¤Î®e¿n¹L±i(Volume overload)ªº¯f¤H¨Ï¥Î3.Digoxin¤£¯à­°§C¦º¤`²v¦ý¥B¦³¤¤¬rªº¦MÀI,¤£À³¨Ï¥Î4.Cardiac resynchronization therapy CRT»ù¿ú°ª¡A¦ý¹ï©Ò¦³¤ßŦ°IºÜªº¯f¤H¦³ÅãµÛÀø®Ä?5¤ßŦ²¾´Ó¬O¥Ø¼ÐªvÀø(Destination therapy)¤U¦C¦óªÌ¬O¥¿½Tªº½×µý?
A.1 + 2 + 3
B.1 + 2 + 4
C.1 + 2 + 5
D.2 + 3 + 4
E.2 + 3 + 5
 
(E) 21.¤@¦ì22·³¹B°Êªø¶]°ª¤â¡A¤é±`¨ÃµL¥ô¦ó²§±`¯gª¬¡A¥u¦³ÅéÀˮɵo²{¤ß¸õ¤ÓºC¡C24¤p®É¤ß¹q¹Ï°O¿ýÅã¥Ü·¥«×Äu©Ê¤ß¸õ½wºC¤¶©ó35 -45/min¡A¹B°Ê¤ß¹q¹Ï¨Ã¥¼¦³¤ß¦Ù¯Ê®ñÅܤơC½Ð°Ý±zªº³B¸m¨BÆJ¬O:
A.¬I¦æ¤ßŦ¶W­µªiÀˬd
B.¬I¦æ¹q®ð¥Í²z¾ÇÀˬd
C.¸Ë¸m¤H¤u¤ß«ß½Õ¸`¾¹
D.¬I¦æ¹B°Ê¤ß¦ÙThallium201Äéª`Åã¼v
E.©w´Á°l°lÂÜÀˬd
 
(C) 22.¦³Ãö¤ßªÍ´_µd³N(CPR)ªº·sªñ¹ê¯gÂå¾Ç½×ÂI¡A¤U¦C¦óªÌ¬O¿ù»~¡H
A.epinephrine°ª¾¯¶q(5-14mg)ªº¤ñ¶Ç²Î¾¯¶q(1mg)¦³§U¤ßŦ´`Àô¤§´_­ì¡A¦ýµL¯q©ó¸£¥\¯à¦^´_¤Î¦º¤`²v¤§§ïµ½
B.ÀR¯ßª`®gsodium bicarbonate¤£¯à§ïµ½¤ß¦Ùªº¥NÁ©ʻĤ¤¬r¡A¤Îventricular f ibrillation ªº²£¥Í
C.¾¨¦­¹ê¬I¤f¹ï¤fªº¤H¤u©I§l¤ñ¤ß¥~«ö¼¯§ó¦³±Ï¬¡¯f¤Hªº¾÷·|
D.·s¦¡ªº Active compression decompression CPR¥i§ïµ½«aª¬°Ê¯ßÄéª`À£¤O¡A¦ý¤´µL§U©ó¦º¤`²v¤§§ïµ½
E.¾¨³t±Ò¥Î¿n·¥Åé¥~¥hŸªvÀø(AED¡^¦³§U©óCPRªº¦¨¥\
 


< ¤E¤Q¤»¦~«×¸ÕÃD¥Ø¿ý >